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Neurite RNA binding proteins are important for neurite growth, a process critical for neuronal development and regeneration after injury. It has
been known that many RNA binding proteins undergo nucleocytoplasmic shuttling but how their nucleocytoplasmic distributions are regulated
during neurite growth has not been well explored. Here we found that the polypyrimidine tract binding protein (PTB) was exported from the
nucleus and accumulated at growing neurite terminals upon activation of the PKA pathway in PC12 cells in a PKA-target Ser16-dependent
manner. RNA interference (RNAi) of PTB significantly disrupted the neurite growth. We then examined the role of cytoplasmic PTB in relation to
mRNAs involved in neurite growth. We found that PTB was preferentially associated with the β-actin mRNA transcripts in cytoplasmic fractions.
RNAi of PTB reduced neurite accumulation of the endogenous actin proteins. It is thus likely that, during PKA-induced neurite growth, PTB is
relocalized through Ser16 phosphorylation to the cytoplasm where it is associated with β-actin mRNA and is critical for the mRNA localization to
neurites.
© 2007 Elsevier B.V. All rights reserved.Keywords: Polypyrimidine tract binding protein; PTB; PKA; Nucleocytoplasmic transport; Neurite growth; Phosphorylation; mRNA localization1. Introduction
RNA binding proteins are important for the asymmetric
distribution of mRNAs in cells from yeast to human [1]. In
neurons, they are involved in mRNA localization and/or neurite
growth [2–18]. For example, two RNA binding proteins ZBP1
and ZBP2 participate in the localization and translation of the
β-actin mRNA through binding to the zipcode of the 3′
untranslated region (3′ UTR) [5,8,17–19]. Particularly, the
ZBP1 protein has been shown to accompany the β-actin mRNA
from the nucleus to the cytoplasm and the neurites, where the
c-Src protein kinase phosphorylates the Tyr396 of ZBP1 for the
actin mRNA to dissociate for translation. It has also been known
that many mRNA binding proteins, including those that are
mainly in the nucleus in the static state, shuttle between the
nucleus and the cytoplasm [20,21]; and that disturbance of this
process and the cytoplasmic localization of the proteins would
affect neurite growth [22]. But there remains no direct⁎ Corresponding author. Tel.: +1 204 975 7774; fax: +1 204 789 3934.
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doi:10.1016/j.bbamcr.2007.02.006molecular link between the nucleocytoplasmic distribution of
RNA binding proteins and neurite-inducing signals.
PTB (hnRNP I) is a member of the heterogeneous nuclear
ribonucleoprotein particle protein (hnRNP) family that are
involved in many aspects of mRNA metabolism [20]. Several
PTB genes have been identified including the commonly known
PTB and nPTB [23–32]. PTB is expressed in neurons only
during the embryonic stages and nPTB in both embryonic and
adult neurons [33]. PTB protein represses alternative pre-mRNA
splicing in the nucleus [23,34], and controls mRNA localization,
stability and viral RNA translation in the cytoplasm [35–39],
through binding to pyrimidine-rich sequences with a consensus
of UUCU, UCUU or CUCU [23,34,40]. In a human embryonic
kidney cell line, the nucleocytoplasmic distribution of PTB can
be regulated by direct PKA phosphorylation of serine 16 (Ser16,
Fig. 1a) [41], a critical residue in the nuclear localization and
export signal domain [41–46]. Specifically, increased Ser16
phosphorylation relocalizes PTB from the nucleus to the
cytoplasm [41]. In pancreatic beta cells, cytoplasmic PTB
controls the stability of the insulin mRNA and the nucleocyto-
plasmic PTB relocalization is important for glucose-induced
Fig. 1. Localization of PTB during forskolin-induced neurite growth. (a) Diagram of PTB phosphorylation by PKA in PC12 and other cells (Xie et al.). The black box
represents the nuclear localization and export signal domain (NLS, NES) and boxes with vertical lines the four RNA recognition motifs (RRMs, not to scale).
(b) Fluorescent images of PC12 cells treated for 8 h with either ethanol or forskolin (10 μM) and stained with either Phalloidin-TRITC (for actin, top panel) or anti-PTB
antibody BB7 (middle and lower panels) as indicated above and to the left of the images. The bottom panel is an enlarged area outlined in the middle panel, with plots of
PTB intensities in the neurites shown under the images. Note the presence of PTB immunoreactivity in the neurite terminals (green, and arrow-pointed) in the forskolin-
treated cells (middle and lower panels). The secondary antibody used for the PTB staining is anti-mouse IgG-fluorescein. No fluorescent signals were seen without the
primary antibody BB7. (c) Time course of the increase in immunoreactivity of neurite terminal PTB and neurite growth after forskolin addition (average±SEM).
Neurite terminal PTB intensity was calculated as the ratio of neurite terminal to nuclear PTB intensity of the same-sized area of the same cells. For each cell, the longest
neurite was measured as neurite length (same as in the following experiments). (d) Localization of the control protein hnRNPA1 (left) 8 h after forskolin addition. No
neurite terminal or cytoplasmic enrichment of A1 protein was observed even under a brighter view. The dotted line in the left image aligns with the path of the neurite
when observed under high contrast. Nuclei (stained with Hoechst 33250) of the same cells are shown to the right to verify the A1 localization in the nucleus. (e)Western
blots of nuclear (lanes 1–2) or cytoplasmic (lanes 3–4) proteins from untreated (lanes 1,3) or forskolin-treated (lanes 2,4, for 4 h) PC12 cells with antibodies against
endogenous PTB, nonphospho-Ser16 (S16, arrow-pointed) or the phospho-Ser16 (pS16) epitope of PTB. The lower band (⁎) in the row of S16 is likely the nPTBwhich
has a similar epitope as PTB (Xie et al.). The S16 signals are much stronger overall than PTB, likely due to differences in the affinity of the antibodies for these epitopes
in rat samples. hnRNP A1 and GAPDH serve as C/N fractionation controls. Blots representative of 4 experiments.
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nucleocytoplasmic distribution of PTB changes and what is the
role of cytoplasmic PTB during neurite growth remain
unknown.
In neurons, the PKA pathway plays a critical role in inducing
neurite growth and is required for mRNA localization in axon
growth cones [19,50–53]. In rat pheochromocytoma PC12
cells, activation of the PKA pathway is sufficient to induceneurite growth [54,55]. Interestingly, phospho-Ser16-PTB is
increased upon activation of PKA in PC12 cells [41]. Thus,
PC12 cells offer an excellent system to study specifically the
effect of the PKA pathway on PTB localization during neurite
growth. Unfortunately, the PC12 cell strain used previously did
not grow neurites efficiently and it is not clear whether the PTB
localization in these cells was changed upon activation of the
PKA pathway.
Fig. 2. Role of the PKA target Ser16 in PTB relocalization by forskolin. (a) Localization of wild type Myc-PTB (WT) and mutants (S16A and S21A) 8 h after ethanol
or forskolin (10 μM) addition, as indicated above the images. Nuclear images of the same cells are shown below the Myc images. The neurite grown in the Myc-PTB
S16A-transfected cells was verified by adjusting the image to brighter and high contrast views. The dotted lines indicate the cell edges or neurites under high contrast.
(b) Average cytoplasmic to nuclear (C/N) Myc-PTB intensity ratios (±SEM) of the samples as in a (***p<0.001, in Student's t-test, same in the followings). C/N was
taken as the ratio of cytoplasmic to nuclear PTB immunoreactivity of the same sized area of the same cells. (c) Average neurite terminal to nuclear (T/N) Myc-PTB
intensity ratios (±SEM) of the samples as in a (***p<0.001). (d) Effect of cycloheximide on PTB relocalization by forskolin. Shown are immunostaining images of
PTB (left) and nuclei (right) of PC12 cells treated with forskolin, with prior addition of cycloheximide (100 μg/ml).
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of PTB during PKA-induced neurite growth, we used a PC12
strain that grew neurites efficiently upon activation of the PKA
pathway [56], and examined the role of Ser16 in the
nucleocytoplasmic distribution of PTB during PKA-induced
neurite growth and cytoplasmic PTB's association with the
mRNA essential for neurite growth.
2. Experimental methods
2.1. Cell culture and transfection
PC12 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)
with 10% horse serum plus 2.5% fetal bovine serum, at 37 °C with 5% CO2.
Transient transfection assays were carried out in 12-well plates (Falcon) using
LipoFectamine 2000 (Invitrogen). Briefly, about 60% confluent PC12 cells of
one 100 mm dish were resuspended and divided equally into each well of 12
well plates and incubated overnight. One and half micrograms of DNA were
mixed with 3 μl of LipoFectamine 2000 in 50 μl of DMEM (serum- and
antibiotics-free) and incubated at room temperature for 10 min. The mixture was
then added to each well. For co-transfection with two plasmids, the volumes of
lipid and DMEMwere proportionally adjusted. After 3 h of incubation, the cellswere supplied with fresh media and cultured for a period of time as specified in
the text. Forskolin (10 μM) was dissolved in ethanol instead of DMSO, which
induces growth of cell processes by itself (data not shown). In experiments with
protein synthesis inhibitor, cycloheximide (100 μg/ml) was applied prior to the
forskolin addition (Fig. 2d).
2.2. Immunostaining
Cover glasses (12 mm in diameter) were coated with poly-D-lysine (0.5 mg/
ml, Sigma) at 4 °C overnight and put one into each well of 12 well plates. PC12
cells were plated over the coated cover glasses. Before staining, cells were rinsed
in cold phosphate-buffered saline with 1% BSA, fixed with pre-chilled 4% PFA
for 15 min and then permeabilized with 0.2% Triton-X 100 for 10 min at room
temperature. The fixed cells were incubated overnight at 4 °C with primary
antibodies, either mouse anti-PTB (BB7 [57], 1:200 dilution), rabbit anti-c-Myc
(1:1000), or mouse anti-hnRNPA1 (1:1000). These cells were then washed and
incubated with anti-mouse or anti-rabbit fluorescent secondary antibodies
(1:1000, conjugated with Texas-Red for red colour or fluorescein for green
colour) for 1 h at room temperature in the dark. Hoechst 33342 (1:5000) or
Phalloidin-TRITC (1:10000) were used to highlight the nuclei or actin of cells in
some experiments. Incubation and washes for the primary antibody were in TBS
(20 mM Tris–Cl, 250 mM NaCl, plus 1% BSA) and for the secondary antibody
in TBS without BSA. The stained cells were observed under fluorescent
microscope (Nikon).
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Briefly, for endogenous proteins, PBS (containing 1 mM EDTA) -washed
cells grown in 100 mm plates were resuspended in 70 μl cold NP40 buffer
[150 mM NaCl, 10 mM Tris (pH 7.8), 1 mM EDTA and 0.3% Igepal CA-630
(Sigma)] and spun down. The pellet was washed with PBS-EDTA, lysed in
140 μl RIPA buffer, sonicated and saved as nuclear fraction. The supernatant
was layered onto a 24% sucrose cushion and spun at 14,000 rpm for 10 min at
4 °C, and then 90% of the upper layer above the sucrose was used as cytoplasmic
fraction. For Western blotting of the PTB proteins, 20 μl of cytoplasmic or 10 μl
of the nuclear fraction was loaded per lane. For Myc-PTB-transfected samples,
two wells of cells grown in 6-well plates and transfected with plasmids (2 μg
each) were similarly lysed and fractionated into 100 μl NP40 (C) or RIPA (N)
buffer, and 10 to 15 μl was loaded per lane. The clean separation of cytoplasm
(C) and nuclear (N) fractions was verified by the absence of hnRNP A1 and
GAPDH proteins in the C and in the N fractions, respectively. Primary
antibodies were incubated with 5% dry milk in TBS buffer containing 500 mM
NaCl. Secondary antibodies were used at a dilution of 3000×. Final washes were
in TBS containing 500 mM NaCl. The blots were then incubated with ECL
reagents and exposed to X-ray films. Before reprobing, the blot membrane was
incubated in stripping buffer (2% SDS, 100 mM β-mercaptoethanol, 50 mM
Tris, pH 6.8) at 65 °C for 30 min.
2.4. Plasmid construction
Target sequences (sense, 5′→3′) of RNAi are chosen from the divergent 3′
UTR of mRNAs and cloned into pSilencer2.1-U6 neo (Ambion). The sequences
tested are as follows (numberings are based on GenBank accession numbers
X60789 for rat PTB [30] and AJ010585 for rat nPTB [27,28]): PTBi1680:
TGACCTTACAGACCAGAG; PTBi2015 (PTBi): TCAAGTGACATGATT
CTCC; PTBi2587: CGACTACAGGCTCAGTATT; PTBsm (scrambled PTBi):
CTCCGAATACATTAGTGTC; PTBm (mutant of PTBi): TCAAGTctCAacAT
TCTCC. nPTBi2230 (nPTBi): TTAACAAGATGCAGAGTAT; nPTBi2353:
GTGTCAGCACTAAGTAATGT; nPTBi2841: GATTCATAGATTCTGTTAT.
All sequences were blasted against the rat genome and no perfect matches with
other genes were observed. They were cloned according to the plasmid
supplier's protocol. Briefly, hairpin oligonucleotides were dissolved with sterile
H2O to 100 μM. Two microliters of each complementary oligonucleotide were
mixed with 16 μl of annealing buffer (10 mM Tris–Cl, pH 7.5; 50 mMNaCl and
1 mM EDTA) and denatured at 95 °C for 5 min, followed by annealing at room
temperature. The annealed oligonucleotides were phosphorylated (2 μl annealed
oligonucleotide, 10 u T4 polynucleotide kinase, 0.1 mM ATP) at 37 °C for
30 min and then incubated at 70 °C for 10 min. The phosphorylated
oligonucleotides were cloned between the HindIII and BamHI sites of the
pSilencer2.1-U6neo vector.
2.5. Gel mobility shift assay
The rat zipcode RNA probe was made by in vitro transcription from a T7-
promoter tagged PCR product of reversed transcribed PC12 cell mRNAs. The
full zipcode sequences used are: 5′-GCGGACUGUUACUGAGCUGC
GUUUUACACCCUUUCUUUGACAAAACCUAACUUGCGCA-3′ (wild
type) and 5′- GCGGACUGUUACUGAGCUGCGUUUUACACCCgUgaUgU
GACAAAACCUAACUUGCGCA-3′ (mutant, mutated nucleotides in lower
cases). Mutations were introduced with a mutant primer. Gel shift assay
conditions are as reported by others [58], except that the interaction buffer was
preincubated with 200 ng/μl of yeast tRNA and the complexes were resolved in
a 4% native polyacrylamide gel.
2.6. Immunoprecipitation-RT-PCR
Three 150-mm dishes of PC12 cells treated with forskolin were lysed in
NP40 cell fractionation buffer (600 μl total). A third of the cytoplasmic fraction
was precleared with protein A-sepharose beads and added 2 μl antibody against
PTB (BB7, ATCC) or hnRNP L (4D11, Santa Cruz), incubated with rocking at
4 °C for 1 h and washed in NP40 buffer with NaCl (300 mM final
concentration). The resulting pellets were extracted for RNA with an RNAextraction kit (Sigma). About 40 ng RNA from the pellet and 400 ng from the
supernatant were used in 10 μl reverse transcription reaction and 1 μl used in
PCR (30 cycles for actin from supernatant and 40 cycles for the rest of the
samples). PCR products were resolved in 3% agarose gel.
2.7. In vitro RNA transcription and probe labelling
Fluorescent UTP was incorporated into the zipcode RNA in in-vitro
transcription reactions. Briefly, PCR fragments carrying a T7 promoter were
purified by agarose gel electrophoresis and used as templates for in vitro
transcription with T7 RNA polymerase. Reaction mixtures (100 μl containing
1× T7 transcription buffer, plus 1.5 mM ATP, 1.5 mM CTP, 1.5 mM GTP,
1.0 mM UTP, 0.02 mM fluorescein-12-UTP, 4 mM MgCl2, 0.5 mM DTT,
500 ng DNA template and 10 μl T7 RNA polymerase) were incubated for
4–6 h at 37 °C, treated with 1u DNase for 30 min, followed by heating at
85 °C for 5 min. The fluorescent RNA probes were then purified by G-25
column. One hundred nanograms of labelled probes were transfected into
PC12 cells using LipoFectamine 2000 according to the manufacturer's
instructions (Invitrogen).
2.8. Image data analysis
The NIH Image J software (developed at the U.S. National Institutes of
Health and available on the Internet at http://rsb.info.nih.gov/ij/) was used to
measure the immunofluorescence intensity. Same sized circle areas were
measured from neurite terminal (T), cytoplasm (C) or nucleus (N) of each cell to
obtain intensity ratios of T/N or C/N. To measure neurite length, the EGFP or
actin images were adjusted to high contrast for a clear view of the neurites. The
longest neurite was measured for each cell's neurite length. For the RNA
interference groups, acquiring images and measurement of the neurite lengths
were carried out with double blind test, where the cover slips prior to imaging
were shuffled in a 12-well plate and identity kept by another person.
2.9. Statistical analysis
The statistical significance of differences between samples was tested with
two-tailed Student's t-test.3. Results
3.1. PTB relocalizes to the cytoplasm and neurite terminals
upon activation of the protein kinase A pathway
To examine the localization of PTB in PKA-mediated neurite
growth, we obtained a PC12 strain that grew neurites efficiently
in response to forsklin or cAMP treatment [56]. In this cell line,
both PTB and nPTB proteins are expressed. Here we will focus
on the PTB protein since its expression in neurons is restricted
to the embryonic stage [33], and mention briefly our data on
nPTB in comparison with PTB.
In untreated or ethanol-treated PC12 cells, neurite growth
was rare and PTB was mainly in the nucleus (Fig. 1b and e). In
cells treated with forskolin, a well known activator of the
adenylate cyclase of the PKA pathway [59], neurites grew to an
average length of 48 μm (±2.24 μm, average±SEM, n=25
cells, Fig. 1b and c) within 8 h. Similar results were obtained by
treatment with a cyclic AMP analogue cpt-cAMP. Moreover,
the forskolin-induced neurite growth was disrupted by a PKA
inhibitor KT5720 (data not shown). Most strikingly, the neurite
terminals were enriched with PTB immunoreactivity in these
cells. The ratio of the neurite terminal to nuclear PTB intensity
(T/N) increases during the outgrowth of neurites (Fig. 1c). This
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in the cell soma and a 15% increase of the cytoplasmic to
nuclear PTB intensity ratio (C/N). In contrast, hnRNP A1,
another shuttling hnRNP protein that is mainly nuclear without
forskolin treatment, still remained in the nucleus and was not
increased in the cytoplasm or enriched at the neurite terminals
after treatment (Fig. 1d). Therefore, the increased cytoplasmic
and neurite localization is specific for the PTB protein rather
than a general effect by forskolin on nuclear factors.
The nPTB protein, mainly cytoplasmic before treatment, also
localized to the neurite terminals but with no obvious changes in
its nucleocytoplasmic distribution upon forskolin treatment
(data not shown).
To verify the relocalization of PTB protein and its
phosphorylation status (phospho-Ser16-PTB) during forskolin
induction, we probed Western blots of cytoplasmic and nuclear
fractions of PC12 cells treated with forskolin, using antibodies
specific for PTB (BB7, recognizing both nonphospho- and
phospho- Ser16-PTB) [41,57], nonphospho-Ser16-PTB (S16),
phospho-Ser16-PTB (pS16), or hnRNPA1 (Fig. 1e). Similar to
the immunostaining result in Fig. 1b, PTB is clearly detectable
with the BB7 antibody in the nucleus but not the cytoplasm
without forskolin treatment (Fig. 1e, lanes 1 and 3). The nuclear
PTB decreased and the cytoplasmic PTB was increased upon
forskolin treatment (lanes 2 and 4). The anti-S16 antibody gave
much stronger signals making the cytoplasmic PTB detectable
even in the non-forskolin sample (lane 3). The nonphospho-
Ser16-PTB (S16) was decreased in the nucleus but not
increased comparably in the cytoplasm upon forskolin treat-
ment. The phospho-Ser16-PTB (pS16) was invisible in both
fractions when no forskolin was added (lanes 1 and 3), but
clearly detected and mainly in the cytoplasmic fraction upon
forskolin treatment (lanes 2 and 4). In contrast, the hnRNP A1
protein band was neither increased in the cytoplasm nor
decreased in the nucleus by forskolin treatment. Thus, the
Western blot data is consistent with the observed PTB
relocalization from nucleus to the cytoplasm by immunostain-
ing (Fig. 1b). Moreover, phospho-Ser16-PTB is sharply
increased in the cytoplasm upon forskolin treatment, supporting
that PKA phosphorylation of PTB is involved in its relocaliza-
tion from the nucleus to the cytoplasm.
3.2. The PKA target S16 is required for PTB relocalization
during neurite growth
To confirm the involvement of the PKA pathway and its
target Ser16 in the PTB relocalization to both the cytoplasm and
neurite terminals upon forskolin treatment, we then examined
the effect of Ser16 mutation on the localization of PTB, with the
previously tested Myc-tagged wild type PTB (WT), the S16A
(serine 16 changed to alanine) or the S21A (serine 21 changed
to alanine) mutant [41].
The wild type Myc-PTB was mainly in the nucleus when
cells were not treated or treated with ethanol, with an average C/
N (cytoplasmic to nuclear Myc-PTB intensity) ratio of 0.51
(±0.03, n=57 cells, Fig. 2a and b). Forskolin treatment
relocalized a substantial amount of Myc-PTB to the cytoplasmwithin 8 h (C/N ratio: 0.93±0.02, n=92 cells). Moreover, these
cells grew neurites similarly as those transfected with the
control plasmid expressing the enhanced green fluorescent
protein (EGFP) and more than half (57%, n=47 cells) of them
contained enriched Myc-PTB at neurite terminals, with an
average T/N ratio of 0.53 (±0.03, n=60 cells). In contrast, the
S16A mutant remained mostly nuclear upon forskolin treat-
ment, with a C/N ratio close to the ethanol-treated wild type
samples (Fig. 2a and b), although these cells still grew out
neurites as verified under brighter views. Moreover, the
presence of the S16A mutant protein at neurite terminals was
reduced to an average T/N ratio of 0.22 (±0.03, n=44 cells).
Both the C/N and T/N ratios of the S16A are significantly lower
than the WT samples (Fig. 2b and c). In comparison, the control
mutant S21Awas similarly relocalized by forskolin as the wild
type Myc-PTB. Therefore, the S16A mutation specifically
abolishes the Myc-PTB relocalization to the cytoplasm and the
neurites in response to forskolin induction. This indicates that
the Ser16 phosphorylation is essential for PTB to relocalize
from the nucleus to the cytoplasm and neurite terminals.
The forskolin-induced Myc-PTB relocalization to the
cytoplasm was not affected by prior application of the protein
synthesis inhibitor cycloheximide (Fig. 2b and d), though the
growth of neurites was drastically disrupted. This suggests that
the cytoplasmic Myc-PTB proteins are mostly exported from
the nucleus rather than newly synthesized after forskolin
addition.
3.3. RNA interference of PTB disrupts neurite growth
Neurite RNA binding proteins and associated mRNAs have
been implicated in neurite growth. The relocalization of PTB to
the neurite terminals by PKA during PKA-induced neurite
growth implies that PTB plays a role at the growing neurite
terminals. We are also aware that the overexpression of Myc-
PTB or its mutants did not affect neurite growth (Fig. 2a);
however, overexpressed PTB may exert complex effects not
seen by endogenous PTB. Therefore, to determine whether
endogenous PTB plays a role in the PKA-mediated neurite
growth, we carried out RNA interference assays against the
expression of PTB.
We first tested PTB sequences as short hairpin RNAs
expressed from silencer plasmids [60]. To visualize the
hairpin RNA-expressing cells, we co-transfected each silencer
plasmid with an EGFP plasmid (Silencer:EGFP=2:1) and the
RNAi effect was monitored 3 days later by immunostaining of
PTB in comparison with the non-EGFP cells in the same
images. Co-transfection of one silencer PTBi2015 (called
PTBi hereafter) with EGFP consistently reduced endogenous
PTB immunoreactivity (up to 60% reduction, average
45±3%, Fig. 3), compared to the non-EGFP cells in the
same images. In contrast, transfection of the EGFP plasmid
alone did not reduce the PTB immunoreactivity (100±4% of
non-EGFP cells in the same images, n=13); neither did the
PTBi control plasmids PTBsm (with scrambled PTBi
sequence) and PTBm (with 4 nucleotide mismatches from
the PTBi sequence).
Fig. 3. Effect of PTB RNAi on forskolin-induced neurite growth. (a) Target sequences used for the PTBi, PTBsm and PTBm plasmids as indicated to the left.
Nucleotides different from the wild type PTB sequence are underlined. (b) Neurite growth of PC12 cells transfected with EGFP alone (left column), EGFP plus PTBi
(second column from left) or plus PTBsm (with scrambled PTBi sequence, third from left), or plus PTBm (with 4 nt mismatches from the PTBi sequence, fourth from
left) for 3 days, and then induced with forskolin for 8 h. Shown are EGFP (green, upper) or PTB (red, lower) images for the same views of each treatment group. The
arrowheads point to the corresponding EGFP-positive cells in the upper panel. The longest neurites (processes) in each image are highlighted with high-contrast areas.
(c) Neurite length decreases with reduced PTB intensity. The length and PTB intensity are relative to that of the non-EGFP cells with the highest PTB intensity in the
same images (from left to right: n=4, 12, 26, 38, 34, 9 cells for each point). (d) Left, average neurite length index X (X, arbitrary unit, ± SEM) of cells transfected with
silencer (columns 2, 3, 6) or control (columns 1, 4, 5) plasmids. ***p<0.001, compared to the group transfected with EGFP only. N=216, 254,135, 246, 155 and 129
cells for columns 1–6, respectively. Right, percent distribution of neurites longer than a given length in the different groups. Result of nPTBi samples is also included.
The longest neurite was measured for each cell. Imaging and measurement of the neurites were carried out with double blind tests as described in Experimental
methods. These data were from 3 experiments.
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silencer PTBi or control plasmids for 3 days, we treated the
cells with forskolin for 8 h and then measured the neurite
length. In cells transfected with EGFP alone, neurites still
grew well (Fig. 3b and d, arbitrary neurite length index:
1.34±0.04, n=216). In contrast, in most cells co-transfected
with EGFP and PTBi, only very short protrusions grew out
(index: 0.88±0.03, n=254). Moreover, in these cells, neurite
length decreased with reduced PTB intensity (Fig. 3c). In
contrast, cells co-transfected with control plasmids PTBsm or
PTBm grew neurites efficiently (index: 1.28±0.04, n=246,and 1.46±0.05, n=155 respectively). Thus, the average
neurite length of the PTBi group is significantly shorter
than that of the control groups.
The percent distribution of neurite length among the RNAi
and control groups also indicates that the PTBi group has
generally much shorter neurites than the others (Fig. 3d, right).
For example, in the PTBi group less than 30% cells grew
neurites with a length index number higher than 1.0 while in the
other groups there were more than 60% cells.
To further support the specificity of the PTBi effect on
neurite growth, another PTB silencer PTBi1680, targeting a
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similarly (Fig. 3d).
Taken together, these results demonstrate that interference
with the expression of the PTB protein disrupts neurite growth
induced by the PKA pathway.
Interestingly, we noticed that the RNAi knockdown of nPTB
also reduced the PKA-induced neurite growth (Fig. 3d, and see
below and Discussion).
3.4. Association of cytoplasmic PTB with β-actin mRNA
Among others, one possibility for the disrupted neurite
growth is a disrupted cytoplasmic function of PTB by PTBi. We
then looked for potential PTB binding sites among the known 3′
UTR RNA elements of genes involved in neurite growth or
elements sufficient to mediate neurite localization of mRNAs.
We noticed the known consensus PTB binding sequences
UUCU and CUCU in at least four mammalian mRNAs: GAP-
43 [61], Tau [62], CaMK IIα [63] and β-actin [64] (Fig. 4).
Particularly β-actin has been known to be involved in axon
growth and its mRNA localization to the growth cone is
stimulated by forskolin or db-cAMP [8,19,65]. The mammalian
β-actin neurite localization signal (called zipcode) sequence
harbours a pyrimidine-rich sequence containing UUCU (Fig. 4),Fig. 4. Potential PTB binding sites in the stability control region rbr1 of the GAP-4
sequences of GAP-43, Tau, CaMK IIα, and β-actin from several species (wherever
names. Boxed are the consensus PTB target motifs in mammals. The underlined bet
corresponding to the chicken zipcode are from sequences with GenBank accessi
AY141970 (bovine) and NM_205518 (chick). The sequences for chimpanzee and mo
(http://www.genome.ucsc.edu/cgi-bin/hgBlat).different from that in the chick zipcode [64]. Preliminary tests
with a rat zipcode RNA probe detected a weak but consistent
and UUCU-dependent interaction with PTB in gel mobility shift
assays (Fig. 5a). Therefore, we focused on β-actin as an
example of neurite mRNA in association with cytoplasmic
PTB.
We first examined the association between the endogenous
β-actin mRNA and PTB in the cytoplasmic fractions of
forskolin-treated PC12 cells by immunoprecipitation with
anti-PTB antibody followed by RNA extraction from the
supernatant or pellet and then RT-PCR, similarly as done for
other proteins [5]. Beta-actin was preferentially amplified from
pellet RNA samples immunoprecipitated by the PTB but not the
hnRNP L antibody (Fig. 5a, lanes 4–6, upper gel). In contrast,
GAPDH was not amplified in any of the IP pellets (lanes 4–6,
bottom gel). Thus, the cytoplasmic PTB protein is preferentially
associated with the β-actin mRNA transcript.
To test whether mutation of the potential PTB binding site
would affect the zipcode RNA localization to neurites, we
transfected fluorescein-labelled rat zipcode wild type or mutant
RNAs into PC12 cells and examined their localization upon
forskolin induction (Fig. 5b). To avoid drastic interruption of
the ZBP1 binding, the pyrimidine-rich motif in the wild type
RNA was replaced in the mutant with the corresponding chick3 mRNA and in neurite localization signals of other mammalian mRNAs. The
available, indicated to the left of each sequence) are shown under the respective
a-actin sequences (ACACCC) are ZBP1 binding motifs. The beta-actin regions
on numbers NM_001101 (human), NM_031144 (rat), NM_007393 (mouse),
nkey are obtained using UCSC BLAT search in the respective genome database
Fig. 5. Association of cytoplasmic PTB with β-actin mRNA transcripts. (a) Gel mobility shift assay of the interaction of PTB and zipcode RNAwild type (WT) or
mutant (Mut) probes. PTB concentrations are 0, 200, 400 and 800 nM from left to right for each probe (∼10 fmol). Mutated sequence region in the probe is indicated
(not to scale) with the UUCU boxed and mutated nucleotides underlined. Gel representative of 3 experiments. (b) An agarose gel of the RT-PCR products of β-actin
(upper) and GAPDH mRNA (lower) extracted from supernatant (lanes 1–3) or pellet (lanes 4–6) of immunoprecipitated cytoplasmic lysates of PC12 cells pre-treated
with forskolin. The antibodies used for immunoprecipitation are for PTB or hnRNP L (L, as control) as indicated above the upper gel. The arrowhead indicates the actin
product and the asterisk a non-specific product. Similar results were obtained from three experiments. (c) Localization of in vitro transcribed (fluorescein-UTP-
labelled) wild type (WT) β-actin zipcode RNA and a mutant of the potential PTB binding site (Mut) in forskolin treated PC12 cells. The wild type and mutant zipcode
RNA sequences are shown on top with the mutated nucleotides underlined. The UUCU motif is boxed and the ZBP1 binding motif ACACCC is marked with a line
above. Note that the mutated nucleotides are chosen from the chick zipcode sequence in Fig. 4. The fluorescent images of neurite zipcode RNA are shown below to the
left, with the dotted lines aligning above the neurites. To the right is a graph of the relative percentages (average±S.D., n=3 experiments) of cells with enrichment of
zipcode RNA at the neurite terminals or with large cytoplasmic RNA granules (>1.25 μm in diameter) of the WT (solid black bars) and Mut (gray bars) RNA.
**p<0.01, ***p<0.001.
919S. Ma et al. / Biochimica et Biophysica Acta 1773 (2007) 912–923non-pyrimidine-rich sequence [66]. The wildtype RNA
appeared as granules in both the cytoplasm and neurite
terminals (Fig. 5c). Its enrichment in neurite terminals was
found in about 70% of cells. In contrast, enrichment of the
mutant RNA at neurite terminals was found in only about 35%
of cells. Examination of their cytoplasmic granules indicates
that mutant RNAs formed more large granules (>1.25 μm in
diameter) than the wild type. The percentages of cells
containing large cytoplasmic granules are about 35% and
60% for the wild type and mutant, respectively. The mutation
thus appears to reduce zipcode RNA enrichment at the neurite
terminals and this is accompanied by the presence of more
large granules inside the cytoplasm. Therefore, the UUCU
sequence region is critical for the zipcode RNA localization to
neurite terminals.
Taken together, these results suggest that the cytoplasmic
PTB is associated with the β-actin mRNA transcripts and is
essential for their localization to neurite terminals.To test whether interference of the PTB protein expression
by RNAi affects the localization of β-actin protein to neurites,
we examined the localization of β-actin protein in PTBi-treated
cells by immunostaining. Neurite terminal accumulation of beta
actin protein is significantly reduced in PTBi cells compared to
others. The relative immunoreactivity of the beta-actin protein
at neurite terminals (compared to that in the middle of the
neurites) is reduced from 3.5 (±1.3, n=4) in cells cotransfected
with PTBsm to 0.8 (±0.3, n=4, p<0.01) in cells transfected
with the PTBi plasmid. Percentage of cells with enriched β-
actin proteins at the neurite terminals was consistently reduced
in the PTBi group (about 44% reduction) compared to that in the
control groups (Fig. 6). PTB is thus required for the enrichment
of β-actin protein at neurite terminals.
The nPTBi cells have reduced actin protein at the neurite
terminals as well (Fig. 6b).
Overall, taking advantage of the PC12 cell neurite growth
model with a specific signalling pathway, we show that during
Fig. 6. The effect of PTBi on the localization of β-actin protein in forskolin-induced cells. (a) Representative fluorescent images (Red) of PC12 cells expressing EGFP,
or EGFP plus PTBi, PTBsm or PTBm plasmids (indicated to the left of each image) and immunostained with anti-β-actin antibody and Texas-Red-conjugated
secondary antibody. Intensity plots of neurite β-actin protein immunoreactivity are shown to the right of each image; the dotted lines align with the neurites and the
neurite terminals are indicated with arrowheads. (b) Bar graph of the percentage (average±S.D., n=3 experiments) of cells (>250 cells each group) with neurite
enrichment of β-actin protein immunoreactivity in the cells in a. Result for the nPTBi cells is also included (at the right). *p<0.05, compared to the EGFP group.
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nucleus and accumulated in a Ser16-dependent manner in the
cytoplasm, where it is associated with specific mRNA
transcripts and is critical for their localization to the neurite
terminals. This is likely at least one way for PTB to control
neurite growth.
4. Discussion
RNA localization and RNA binding proteins are known
involved in neurite growth [2]. Many RNA binding proteins are
multifunctional in both the nucleus and cytoplasm and their
distribution can be controlled through nucleocytoplasmic
shuttling [20,21]. It has not been clear how the nucleocyto-
plasmic distribution of RNA binding proteins is regulated by
neurite-inducing signals during neurite growth and their roles inthe cytoplasm. In the present study, we examined the
localization of PTB during PKA-induced neurite growth and
its association with cytoplasmic mRNA transcripts essential for
neurite growth, and show that the Ser16 of PTB is critical for its
relocalization to the cytoplasm and neurites upon PKA
activation during neurite growth. The cytoplasmic PTB is
preferentially associated with the β-actin mRNA and PTB
reduction by RNAi affects actin protein localization to the
neurite terminals. Without excluding the role of nuclear PTB in
mRNA processing [23,67–69], these data suggest that shift of
the nucleocytoplasmic distribution of PTB likely plays a role in
the localization of target neurite mRNAs during PKA-induced
neurite growth.
In the cytoplasm, PTB regulates mRNA localization or
stability through binding to the pyrimidine-rich elements of the
3′ UTR [35,38,47,70]. Particularly relevant to neurite growth is
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rbr1 region of the growth-associated protein-43 (GAP-43)
mRNA upon NGF stimulation of PC12 cells [61]. Thus,
stabilization of the GAP-43 mRNA by nPTB, possibly PTB as
well, could be one way for them to contribute to neurite growth;
however, this does not explain why PTB needs to be localized to
the neurite terminals during neurite growth.
To explore the role of PTB in association with a cytoplasmic
mRNA known to be localized in neurites during neurite growth,
we took β-actin mRNA as an example to investigate. Beta-actin
mRNA localization has been known to be essential for cell
motility and neuronal axon growth [18]. Our results indicate
that PTB is associated with the β-actin mRNA in the cytoplasm
(Fig. 5). Taken together with the reduced neurite localization of
the zipcode mutant RNA (Fig. 5b), it is likely that PTB is
involved in the actin mRNA localization to neurites.
Cytoplasmic PTB is known to control the localization or
metabolism of several other RNA transcripts, including the Vg1
mRNA in Xenopus oocytes [35], viral RNAs [39,71], insulin
mRNA in pancreatic beta cells [47,49], and CD154 mRNA in
immune cells [38]. In the case of insulin mRNA, glucose-
induced PTB relocalization to the cytoplasm through Ser16
phosphorylation stabilizes the insulin mRNA and upregulates
the biogenesis of insulin granules [47]. PTB may also control
GAP-43 mRNA stability during neurite growth [61], consider-
ing the similarity between the target sequences of PTB and
nPTB. The mammalian Tau mRNA also contains the consensus
PTB binding site in its neurite localization signal (Fig. 4). A
recent large scale analysis in HeLa cells indicates that PTB-
associated transcripts are enriched in mRNA species that
encode proteins implicated in intracellular transport, vesicle
trafficking and apoptosis [72]. Therefore, the cytoplasmic PTB
is likely associated with a diverse group of mRNAs to control
their localization or metabolism to regulate cell/virus functions
during development, in viral infection, in endocrine secretion,
immune response and neurite growth. It will be interesting to
characterize these and other mRNAs that are associated with
PTB to determine the role of cytoplasmic PTB in cell functions.
The shift of the nucleocytoplasmic distribution of PTB
controlled by cell signalling likely represents a common
theme for PTB to function appropriately in both the nucleus
and cytoplasm according to cell's physiological requirements.
With diverse mRNA targets of PTB in the cytoplasm
identified and the regulated nucleocytoplasmic distribution of
PTB shown, one may wonder where inside a cell these target
mRNAs start to be associated with PTB. In the case of ZBP1,
the beta-actin mRNA is accompanied by ZBP1 in the nucleus to
the cytoplasm and neurites [17]. It has been known that some
splicing factors in the nucleus deposit in the exon–exon
junction (EJC) complex and accompany the mRNA to export to
the cytoplasm [73]. Interestingly a recent report suggests that
nuclear PTB likely facilitates the export of spliced HIV-1 RNA
transcripts and increase their accumulation in the cytoplasm to
reverse viral latency [39]. However, there is also a report
demonstrating that the nuclear export of PTB is uncoupled from
mRNA synthesis [45]. Thus, it remains unclear where the PTB
target cytoplasmic mRNAs start to be associated with PTB andwhether PTB deposits in the EJC complex after splicing to
accompany RNA to the cytoplasm.
Other inducers such as NGF also induce neurite growth in
PC12 cells but involving more complex signalling pathways
[74]. We did not observe an effect for PTBi on NGF-induced
neurite growth in an experiment with the PC12 cells (Ma and
Xie, unpublished observation). Whether the PTBi effect on
neurite growth in PC12 cells is limited to the PKA pathway is an
interesting question for further investigation.
PTB and nPTB have similar binding sequences but can have
different functions in other assays [24]. Unlike Myc-PTB
overexpression (Fig. 2a and related text), nPTB overexpression
suppresses neurite growth in PC12 cells [27]. Moreover, RNA
interference of either PTB or nPTB disrupts forskolin-induced
neurite growth (Fig. 3d), indicating that during neurite growth
they have non-complementary functions, in addition to their
both involvement in β-actin protein localization in the PKA-
induced neurite growth. It will be interesting to know what these
functions are and the underlying molecular basis.
In summary, using the PC12 cell model system with a well-
known specific PKA pathway sufficient to induce neurite
growth, we show that PTB, a primarily nuclear RNA binding
protein, is relocalized to the cytoplasm and neurite terminals
during PKA-induced neurite growth. This relocalization is
mediated by PKA phosphorylation of Ser16. Moreover, the
cytoplasmic PTB is associated with β-actin mRNA and reduc-
tion of PTB by RNAi affects the β-actin protein localization to
neurites and PKA-induced neurite growth. This provides an
inducible system for tracking down and studying the molecular
details of an RNA binding protein, along its path from the
nucleus to neurite terminals during neurite outgrowth. Studying
these dynamic processes will provide insights into the mole-
cular basis of neurite growth control by localized mRNA and
RNA binding proteins and will be helpful for us to understand
neurite growth during brain development and repair of neurons
after injury.
Acknowledgements
We thank Jim Nagy for PC12 cells, Etienne Leygue, Doug
Black, Robert Shiu, Qiang Wu, Jim Nagy, Angus Nairn, Yaling
Zhou, Wenguang Cao, Mansoreh Nazari, Jiming Kong, Amy
Pandya, Geetanjali Chawla, Ivan Babic, Peter Cattini, Janice
Dodd and Mary Lynn Duckworth for their help or critical
comments. We are grateful to Doug Black for plasmids and
antibodies. Supported to J.X. by the Manitoba Medical Service
Foundation, Manitoba Health Research Council and in part by
the Canadian Institutes of Health Research (CIHR). J.X. is a
CIHR New Investigator and a recipient of CFI fund.
References
[1] C.L. de Hoog, L.J. Foster, M. Mann, RNA and RNA binding proteins
participate in early stages of cell spreading through spreading initiation
centers, Cell 117 (2004) 649–662.
[2] O. Steward, Translating axon guidance cues, Cell 110 (2002) 537–540.
[3] O. Steward, mRNA localization in neurons: a multipurpose mechanism?
Neuron 18 (1997) 9–12.
922 S. Ma et al. / Biochimica et Biophysica Acta 1773 (2007) 912–923[4] S.J. Tang, D. Meulemans, L. Vazquez, N. Colaco, E. Schuman, A role for a
rat homolog of staufen in the transport of RNA to neuronal dendrites,
Neuron 32 (2001) 463–475.
[5] W. Gu, F. Pan, H. Zhang, G.J. Bassell, R.H. Singer, A predominantly
nuclear protein affecting cytoplasmic localization of beta-actin mRNA in
fibroblasts and neurons, J. Cell Biol. 156 (2002) 41–51.
[6] H.L. Zhang, T. Eom, Y. Oleynikov, S.M. Shenoy, D.A. Liebelt, J.B.
Dictenberg, R.H. Singer, G.J. Bassell, Neurotrophin-induced transport of a
beta-actin mRNP complex increases beta-actin levels and stimulates
growth cone motility, Neuron 31 (2001) 261–275.
[7] B. Ye, C. Petritsch, I.E. Clark, E.R. Gavis, L.Y. Jan, Y.N. Jan, Nanos and
Pumilio are essential for dendrite morphogenesis in Drosophila peripheral
neurons, Curr. Biol. 14 (2004) 314–321.
[8] D.M. Tiruchinapalli, Y. Oleynikov, S. Kelic, S.M. Shenoy, A. Hartley, P.K.
Stanton, R.H. Singer, G.J. Bassell, Activity-dependent trafficking and
dynamic localization of zipcode binding protein 1 and beta-actin mRNA in
dendrites and spines of hippocampal neurons, J. Neurosci. 23 (2003)
3251–3261.
[9] P.B. Crino, J. Eberwine, Molecular characterization of the dendritic growth
cone: regulated mRNA transport and local protein synthesis, Neuron 17
(1996) 1173–1187.
[10] P. Litman, J. Barg, L. Rindzoonski, I. Ginzburg, Subcellular localization of
tau mRNA in differentiating neuronal cell culture: implications for
neuronal polarity, Neuron 10 (1993) 627–638.
[11] S. Layalle, E. Coessens, A. Ghysen, C. Dambly-Chaudiere, Smooth, a
hnRNP encoding gene, controls axonal navigation in Drosophila, Genes
Cells 10 (2005) 119–125.
[12] W. Rossoll, S. Jablonka, C. Andreassi, A.K. Kroning, K. Karle, U.R.
Monani, M. Sendtner, Smn, the spinal muscular atrophy-determining gene
product, modulates axon growth and localization of beta-actin mRNA in
growth cones of motoneurons, J. Cell Biol. 163 (2003) 801–812.
[13] A.J. Hannan, P. Gunning, P.L. Jeffrey, R.P. Weinberger, Structural
compartments within neurons: developmentally regulated organization of
microfilament isoform mRNA and protein, Mol. Cell. Neurosci. 11 (1998)
289–304.
[14] J. Eberwine, K. Miyashiro, J.E. Kacharmina, C. Job, Local translation of
classes of mRNAs that are targeted to neuronal dendrites, Proc. Natl. Acad.
Sci. U. S. A. 98 (2001) 7080–7085.
[15] M. Yano, H.J. Okano, H. Okano, Involvement of Hu and heterogeneous
nuclear ribonucleoprotein K in neuronal differentiation through p21
mRNA post-transcriptional regulation, J. Biol. Chem. 280 (2005)
12690–12699.
[16] R. Fujii, S. Okabe, T. Urushido, K. Inoue, A. Yoshimura, T. Tachibana, T.
Nishikawa, G.G. Hicks, T. Takumi, The RNA binding protein TLS is
translocated to dendritic spines by mGluR5 activation and regulates spine
morphology, Curr. Biol. 15 (2005) 587–593.
[17] S. Huttelmaier, D. Zenklusen, M. Lederer, J. Dictenberg, M. Lorenz, X.
Meng, G.J. Bassell, J. Condeelis, R.H. Singer, Spatial regulation of beta-
actin translation by Src-dependent phosphorylation of ZBP1, Nature 438
(2005) 512–515.
[18] J. Condeelis, R.H. Singer, How and why does beta-actin mRNA target?
Biol. Cell 97 (2005) 97–110.
[19] H.L. Zhang, R.H. Singer, G.J. Bassell, Neurotrophin regulation of beta-
actin mRNA and protein localization within growth cones, J. Cell Biol. 147
(1999) 59–70.
[20] A.M. Krecic, M.S. Swanson, hnRNP complexes: composition, structure,
and function, Curr. Opin. Cell Biol. 11 (1999) 363–371.
[21] W.M. Michael, Nucleocytoplasmic shuttling signals: two for the price of
one, Trends Cell Biol. 10 (2000) 46–49.
[22] K. Kasashima, K. Terashima, K. Yamamoto, E. Sakashita, H. Sakamoto,
Cytoplasmic localization is required for the mammalian ELAV-like protein
HuD to induce neuronal differentiation, Genes Cells 4 (1999) 667–683.
[23] E.J. Wagner, M.A. Garcia-Blanco, Polypyrimidine tract binding protein
antagonizes exon definition, Mol. Cell. Biol. 21 (2001) 3281–3288.
[24] V. Markovtsov, J.M. Nikolic, J.A. Goldman, C.W. Turck, M.Y. Chou, D.L.
Black, Cooperative assembly of an hnRNP complex induced by a tissue-
specific homolog of polypyrimidine tract binding protein, Mol. Cell. Biol.
20 (2000) 7463–7479.[25] A.D. Polydorides, H.J. Okano, Y.Y.L. Yang, G. Stefani, R.B. Darnell, A
brain-enriched polypyrimidine tract-binding protein antagonizes the ability
of Nova to regulate neuron-specific alternative splicing, Proc. Natl. Acad.
Sci. U. S. A. 97 (2000) 6350–6355.
[26] C. Gooding, P. Kemp, C.W. Smith, A novel polypyrimidine tract-binding
protein paralog expressed in smooth muscle cells, J. Biol. Chem. 278
(2003) 15201–15207.
[27] M. Ichikawa, T. Kikuchi, H. Tateiwa, N. Gotoh, K. Ohta, J. Arai, N.
Yoshimura, Role of PTB-like protein, a neuronal RNA-binding protein,
during the differentiation of PC12 cells, J. Biochem. (Tokyo) 131 (2002)
861–868.
[28] T. Kikuchi, M. Ichikawa, J. Arai, H. Tateiwa, L. Fu, K. Higuchi, N.
Yoshimura, Molecular cloning and characterization of a new neuron-
specific homologue of rat polypyrimidine tract binding protein, J. Biochem.
(Tokyo) 128 (2000) 811–821.
[29] A. Gil, P.A. Sharp, S.F. Jamison, M.A. Garcia-Blanco, Characterization of
cDNAs encoding the polypyrimidine tract-binding protein, Genes Dev. 5
(1991) 1224–1236.
[30] F. Brunel, P.M. Alzari, P. Ferrara, M.M. Zakin, Cloning and sequencing of
PYBP, a pyrimidine-rich specific single strand DNA-binding protein,
Nucleic Acids Res. 19 (1991) 5237–5245.
[31] J.G. Patton, S.A. Mayer, P. Tempst, B. Nadal-Ginard, Characterization and
molecular cloning of polypyrimidine tract-binding protein: a component of
a complex necessary for pre-mRNA splicing, Genes Dev. 5 (1991)
1237–1251.
[32] A.L. Bothwell, D.W. Ballard, W.M. Philbrick, G. Lindwall, S.E. Maher,
M.M. Bridgett, S.F. Jamison, M.A. Garcia-Blanco, Murine polypyrimidine
tract binding protein. Purification, cloning, and mapping of the RNA
binding domain, J. Biol. Chem. 266 (1991) 24657–24663.
[33] K. Lillevali, A. Kulla, T. Ord, Comparative expression analysis of the
genes encoding polypyrimidine tract binding protein (PTB) and its neural
homologue (brPTB) in prenatal and postnatal mouse brain, Mech. Dev.
101 (2001) 217–220.
[34] D.L. Black, Mechanisms of Alternative Pre-Messenger RNA Splicing,
Annu. Rev. Biochem. 27 (2003) 27.
[35] C.A. Cote, D. Gautreau, J.M. Denegre, T.L. Kress, N.A. Terry, K.L.
Mowry, A Xenopus protein related to hnRNP I has a role in cytoplasmic
RNA localization, Mol. Cell 4 (1999) 431–437.
[36] A. Borman, M.T. Howell, J.G. Patton, R.J. Jackson, The involvement of a
spliceosome component in internal initiation of human rhinovirus RNA
translation, J. Gen. Virol. 74 (1993) 1775–1788.
[37] K.P. Knoch, H. Bergert, B. Borgonovo, H.D. Saeger, A. Altkruger, P.
Verkade, M. Solimena, Polypyrimidine tract-binding protein promotes
insulin secretory granule biogenesis, Nat. Cell Biol. 6 (2004) 207–214.
[38] P.A. Kosinski, J. Laughlin, K. Singh, L.R. Covey, A complex containing
polypyrimidine tract-binding protein is involved in regulating the stability
of CD40 ligand (CD154) mRNA, J. Immunol. 170 (2003) 979–988.
[39] K.G. Lassen, K.X. Ramyar, J.R. Bailey, Y. Zhou, R.F. Siliciano, Nuclear
retention of multiply spliced HIV-1 RNA in resting CD4+ T cells, PLoS
Pathog. 2 (2006) e68.
[40] R. Singh, J. Valcarcel, M.R. Green, Distinct binding specificities and
functions of higher eukaryotic polypyrimidine tract-binding proteins,
Science 268 (1995) 1173–1176.
[41] J. Xie, J.A. Lee, T.L. Kress, K.L. Mowry, D.L. Black, Protein kinase A
phosphorylation modulates transport of the polypyrimidine tract-binding
protein, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8776–8781.
[42] I. Perez, J.G. McAfee, J.G. Patton, Multiple RRMs contribute to RNA
binding specificity and affinity for polypyrimidine tract binding protein,
Biochemistry 36 (1997) 11881–11890.
[43] M.G. Romanelli, F. Weighardt, G. Biamonti, S. Riva, C. Morandi,
Sequence determinants for hnRNP I protein nuclear localization, Exp. Cell
Res. 235 (1997) 300–304.
[44] M.G. Romanelli, C. Morandi, Importin alpha binds to an unusual bipartite
nuclear localization signal in the heterogeneous ribonucleoprotein type I,
Eur. J. Biochem. 269 (2002) 2727–2734.
[45] R.V. Kamath, D.J. Leary, S. Huang, Nucleocytoplasmic shuttling of
polypyrimidine tract-binding protein is uncoupled from RNA export, Mol.
Biol. Cell 12 (2001) 3808–3820.
923S. Ma et al. / Biochimica et Biophysica Acta 1773 (2007) 912–923[46] B. Li, T.S.B. Yen, Characterization of the nuclear export signal of
polypyrimidine tract-binding protein, J. Biol. Chem. 277 (2002)
10306–10314.
[47] K.P. Knoch, R. Meisterfeld, S. Kersting, H. Bergert, A. Altkruger, C.
Wegbrod, M. Jager, H.D. Saeger, M. Solimena, cAMP-dependent
phosphorylation of PTB1 promotes the expression of insulin secretory
granule proteins in beta cells, Cell. Metab. 3 (2006) 123–134.
[48] R.G. Fred, N. Welsh, Increased expression of polypyrimidine tract binding
protein results in higher insulin mRNA levels, Biochem. Biophys. Res.
Commun. 328 (2005) 38–42.
[49] L. Tillmar, N. Welsh, Glucose-induced binding of the polypyrimidine tract-
binding protein (PTB) to the 3′-untranslated region of the insulin mRNA
(ins-PRS) is inhibited by rapamycin, Mol. Cell. Biochem. 260 (2004)
85–90.
[50] R.E. Rydel, L.A. Greene, cAMP analogs promote survival and neurite
outgrowth in cultures of rat sympathetic and sensory neurons indepen-
dently of nerve growth factor, Proc. Natl. Acad. Sci. U. S. A. 85 (1988)
1257–1261.
[51] H.J. Song, M.M. Poo, Signal transduction underlying growth cone
guidance by diffusible factors, Curr. Opin. Neurobiol. 9 (1999) 355–363.
[52] J. Qiu, D. Cai, M.T. Filbin, A role for cAMP in regeneration during
development and after injury, Prog. Brain Res. 137 (2002) 381–387.
[53] W.D. Snider, F.Q. Zhou, J. Zhong, A. Markus, Signaling the pathway to
regeneration, Neuron 35 (2002) 13–16.
[54] P.W. Gunning, G.E. Landreth, M.A. Bothwell, E.M. Shooter, Differential
and synergistic actions of nerve growth factor and cyclic AMP in PC12
cells, J. Cell Biol. 89 (1981) 240–245.
[55] P.W. Gunning, P.C. Letourneau, G.E. Landreth, E.M. Shooter, The action
of nerve growth factor and dibutyryl adenosine cyclic 3′:5′-monopho-
sphate on rat pheochromocytoma reveals distinct stages in the mechanisms
underlying neurite outgrowth, J. Neurosci. 1 (1981) 1085–1095.
[56] J.I. Nagy, J. Hacking, U.N. Frankenstein, E.A. Turley, Requirement of the
hyaluronan receptor RHAMM in neurite extension and motility as
demonstrated in primary neurons and neuronal cell lines, J. Neurosci. 15
(1995) 241–252.
[57] M.Y. Chou, J.G. Underwood, J. Nikolic, M.H. Luu, D.L. Black, Multisite
RNA binding and release of polypyrimidine tract binding protein during
the regulation of c-src neural-specific splicing, Mol. Cell 5 (2000)
949–957.
[58] B. Amir-Ahmady, P.L. Boutz, V. Markovtsov, M.L. Phillips, D.L. Black,
Exon repression by polypyrimidine tract binding protein, RNA 11 (2005)
699–716.
[59] K.B. Seamon, W. Padgett, J.W. Daly, Forskolin: unique diterpene activator
of adenylate cyclase in membranes and in intact cells, Proc. Natl. Acad.
Sci. U. S. A. 78 (1981) 3363–3367.[60] G.J. Hannon, J.J. Rossi, Unlocking the potential of the human genome
with RNA interference, Nature 431 (2004) 371–378.
[61] N. Irwin, V. Baekelandt, L. Goritchenko, L.I. Benowitz, Identification of
two proteins that bind to a pyrimidine-rich sequence in the 3′-untranslated
region of GAP-43 mRNA, Nucleic Acids Res. 25 (1997) 1281–1288.
[62] J.C. Larcher, L. Gasmi, W. Viranaicken, B. Edde, R. Bernard, I. Ginzburg,
P. Denoulet, Ilf3 and NF90 associate with the axonal targeting element of
Tau mRNA, FASEB J. 18 (2004) 1761–1763.
[63] Y. Mori, K. Imaizumi, T. Katayama, T. Yoneda, M. Tohyama, Two cis-
acting elements in the 3′ untranslated region of alpha-CaMKII regulate its
dendritic targeting, Nat. Neurosci. 3 (2000) 1079–1084.
[64] E.H. Kislauskis, X. Zhu, R.H. Singer, Sequences responsible for
intracellular localization of beta-actin messenger RNA also affect cell
phenotype, J. Cell Biol. 127 (1994) 441–451.
[65] Y. Oleynikov, R.H. Singer, Real-time visualization of ZBP1 association
with beta-actin mRNA during transcription and localization, Curr. Biol. 13
(2003) 199–207.
[66] A.F. Ross, Y. Oleynikov, E.H. Kislauskis, K.L. Taneja, R.H. Singer,
Characterization of a beta-actin mRNA zipcode-binding protein, Mol.
Cell. Biol. 17 (1997) 2158–2165.
[67] H. Lou, R.F. Gagel, S.M. Berget, An intron enhancer recognized by
splicing factors activates polyadenylation, Genes Dev. 10 (1996) 208–219.
[68] P. Castelo-Branco, A. Furger, M. Wollerton, C. Smith, A. Moreira, N.
Proudfoot, Polypyrimidine tract binding protein modulates efficiency of
polyadenylation, Mol. Cell. Biol. 24 (2004) 4174–4183.
[69] C. Le Sommer, M. Lesimple, A. Mereau, S. Menoret, M.R. Allo, S. Hardy,
PTB regulates the processing of a 3′-terminal exon by repressing both
splicing and polyadenylation, Mol. Cell. Biol. 25 (2005) 9595–9607.
[70] A. Pautz, K. Linker, T. Hubrich, R. Korhonen, S. Altenhofer, H. Kleinert,
The polypyrimidine tract binding protein (PTB) is involved in the post-
transcriptional regulation of human iNOS expression, J. Biol. Chem. 281
(2006) 32294–32302.
[71] S.H. Back, Y.K. Kim, W.J. Kim, S. Cho, H.R. Oh, J.-E. Kim, S.K. Jang,
Translation of polioviral mRNA is inhibited by cleavage of polypyrimidine
tract-binding proteins executed by polioviral 3Cpro, J. Virol. 76 (2002)
2529–2542.
[72] M. Gama-Carvalho, N.L. Barbosa-Morais, A.S. Brodsky, P.A. Silver, M.
Carmo-Fonseca, Genome wide identification of functionally distinct
subsets of cellular mRNAs associated with two nucleocytoplasmic-
shuttling mammalian splicing factors, Genome Biol. 7 (2006) R113.
[73] R. Reed, Coupling transcription, splicing and mRNA export, Curr. Opin.
Cell Biol. 15 (2003) 326–331.
[74] D. Vaudry, P.J. Stork, P. Lazarovici, L.E. Eiden, Signaling pathways for
PC12 cell differentiation: making the right connections, Science 296
(2002) 1648–1649.
